Journal of Clinical Medicine and Research
Subscribe to JCMR
Full Name*
Email Address*

Article Number - AA29A7453113


Vol.7(2), pp. 7-10 , April 2015
DOI: 10.5897/JCMR2014.0253
ISSN: 2141-2235



Full Length Research Paper

Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon



Lijie Han
  • Lijie Han
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Huifang Zhao
  • Huifang Zhao
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Qingsong Yin
  • Qingsong Yin
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Lin Chen
  • Lin Chen
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Yongping Song
  • Yongping Song
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Xudong Wei*
  • Xudong Wei*
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar







 Received: 08 July 2014  Accepted: 17 April 2015  Published: 30 April 2015

Copyright © 2015 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


Mantle cell lymphoma (MCL) is a highly aggressive non-Hodgkin's lymphoma with poor prognosis. This study aims to explore a new, safe approach for patients with recurrent refractory MCL. A total of six patients with recurrent refractory MCL were recruited. They all accepted thalidomide tablets (100 mg/day) orally every night, accompanied with interferon α-2b (3 million units, injected subcutaneously) every other day. The patients were followed up for 41, 25, 20, 30, 40 and 36 months, respectively, with a median follow-up time of 33 months (20 to 41 months). No severe adverse reactions occurred. For patients with recurrent refractory MCL, the combination of thalidomide and interferon α-2b showed a positive result to provide them a longer survival period with higher quality of life.

 

Key words: Recurrent refractory mantle cell lymphoma, thalidomide, interferon α-2b, combination, adverse reaction.

Armitage JO, Coiffier B (2000). Activity of interferon-α in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann. Oncol. 11(3)359-361.
Crossref
 
D'Amato RJ, Loughran MS, Flynn E, Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:4082-4085.
Crossref
 
Damaj G, Lefrere F, Delarue R, Varet B, Furman R, Hermine O (2003). Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17(9):1914-1915.
Crossref
 
Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1):210-216.
Crossref
 
Davis TA, Maloney DG, Grillo AJ (2000). Combination immunotherapy of relapsed or refractory lowgrade or follicular non-Hodgkin's lymphoma with rituximab and interferonα-2a. Clin. Cancer Res. 6:2644-2652.
Pubmed
 
Haslett PAJ, Corral LG, Albert M, Kaplan G (1998). Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187(11)1885-1892.
Crossref
 
Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J (2004). Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle eell lymphoma. Blood 104(8):2269-2271.
Crossref
 
Richardson P, Hidershima T, Anderson K (2002). Thalidomide: Emerging role in cancer medicine. Ann. Rev. Med. 53:629-657.
Crossref
 
Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G (2001). Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 86(9):951-958.
Pubmed
 
Wilson EA, Jobanputra S, Jackson R, Parker AN, McQuaker IG (2002). Response to thalidomide in chemotherapy-resistant mantle cell lymphoma:a case report.Br. J. HaematoI. 119(1)128-130.
Crossref

 


APA Han, L., Zhao, H., Yin, Q., Chen, L., Song, Y., & Wei, X. (2015). Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon. Journal of Clinical Medicine and Research, 7(2), 7-10.
Chicago Lijie Han, Huifang Zhao, Qingsong Yin, Lin Chen, Yongping Song and Xudong Wei. "Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon." Journal of Clinical Medicine and Research 7, no. 2 (2015): 7-10.
MLA Lijie Han, et al. "Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon." Journal of Clinical Medicine and Research 7.2 (2015): 7-10.
   
DOI 10.5897/JCMR2014.0253
URL http://academicjournals.org/journal/JCMR/article-abstract/AA29A7453113

Subscription Form